Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
| dc.contributor.author | Zugasti, Inés | |
| dc.contributor.author | Tormo Ratera, Marta | |
| dc.contributor.author | Oliver Caldés, Aina | |
| dc.contributor.author | Soler Perromat, Juan Carlos | |
| dc.contributor.author | González Calle, Verónica | |
| dc.contributor.author | Moreno Fajardo, David Fernando | |
| dc.contributor.author | Cabañas, Valentín | |
| dc.contributor.author | López Muñoz, Nieves | |
| dc.contributor.author | Bartolomé Solanas, Álvaro | |
| dc.contributor.author | Español Rego, Marta | |
| dc.contributor.author | Reguera Ortega, Juan Luis | |
| dc.contributor.author | Rosiñol Dachs, Laura | |
| dc.contributor.author | López Corral, Lucía | |
| dc.contributor.author | Tovar Gomis, Natalia | |
| dc.contributor.author | Rodríguez Lobato, Luis Gerardo | |
| dc.contributor.author | Alvarez Perez, Rosa María | |
| dc.contributor.author | Varea, Sara | |
| dc.contributor.author | Olesti Muñoz, Eulàlia | |
| dc.contributor.author | Gómez Grande, Aldofo | |
| dc.contributor.author | Frutos, Laura | |
| dc.contributor.author | Tamayo, Pilar | |
| dc.contributor.author | Juan, Manel | |
| dc.contributor.author | Urbano Ispizua, Álvaro | |
| dc.contributor.author | Moraleda, José María | |
| dc.contributor.author | González Navarro, E. Azucena | |
| dc.contributor.author | Martínez López, Joaquín | |
| dc.contributor.author | Mateos, María Victoria | |
| dc.contributor.author | Tomás Batlle, Xavier | |
| dc.contributor.author | Setoain Perego, Xavier | |
| dc.contributor.author | Fernández de Larrea, Carlos José | |
| dc.date.accessioned | 2026-10-23T13:29:16Z | |
| dc.date.available | 2026-10-23T13:29:16Z | |
| dc.date.issued | 2025-02-11 | |
| dc.date.updated | 2026-10-23T13:29:16Z | |
| dc.description.abstract | Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]–targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11. | |
| dc.format.extent | 12 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 767064 | |
| dc.identifier.idimarina | 9462430 | |
| dc.identifier.issn | 2473-9529 | |
| dc.identifier.pmid | 39602341 | |
| dc.identifier.uri | https://hdl.handle.net/2445/232302 | |
| dc.language.iso | eng | |
| dc.publisher | American Society of Hematology | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024014360 | |
| dc.relation.ispartof | Blood Advances, 2025, vol. 9, num.3, p. 571-582 | |
| dc.relation.uri | https://doi.org/10.1182/bloodadvances.2024014360 | |
| dc.rights | cc-by-nc-nd (c) American Society of Hematology, 2025 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject.classification | Mieloma múltiple | |
| dc.subject.classification | Immunoteràpia | |
| dc.subject.classification | Cèl·lules T | |
| dc.subject.other | Multiple myeloma | |
| dc.subject.other | Immunotheraphy | |
| dc.subject.other | T cells | |
| dc.title | Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1